Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 3 3Phase NA 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 129Recurrence 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 12Lymphoma, Non-Hodgkin 12Lymphoma 12Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Neoplasm Metastasis 8Leukemia 8Burkitt Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Hodgkin Disease 7Prostatic Neoplasms 6Leukemia, Biphenotypic, Acute 5Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Hematologic Diseases 3Colorectal Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Sarcoma 2Rectal Neoplasms 2

Interventions

miridesap 3Dexamethasone 2Calcium Dobesilate 2venetoclax 1pomalidomide 1pegfilgrastim 1Technetium Tc 99m Pyrophosphate 1Technetium 1Surveys and Questionnaires 1Melphalan 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Amyloidosis × Dexamethasone × Clear all
NCT03000660 2020-08-21

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Tufts Medical Center

Phase 1 Terminated
3 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Plasma cell

Amyloidosis, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡